CAI
What one share of Caris Life Sciences holds
Services – Medical Laboratories
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.49 |
|---|---|
| Profit | $0.37 |
| Capex (buildings and equipment) | $0.16 |
| Free cash flow | $0.44 |
| Debt | $1.39 |
| Book value | $2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $8.76 | −$13.24 | $0.64 | −$8.54 | — | −$61.38 |
| 2024 | $11.61 | −$10.66 | $0.24 | −$7.15 | — | −$68.45 |
| 2025 | $4.86 | −$3.22 | $0.10 | $0.40 | — | $2.04 |